来自异基因造血细胞移植后植入患者的全嵌合 CAR.CIK：跨主要人类白细胞抗原屏障的可行性、抗白血病潜力和同种反应性

Cytokine-induced killer lymphocytes (CIK) are a promising alternative to conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic cell transplantation (HCT), due to their intrinsic anti-tumour activity and reduced risk of graft-versus-host disease (GVHD).

We explored the feasibility, anti-leukaemic activity and alloreactive risk of CIK generated from full-donor chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor (CAR) (fcCAR. CIK) against the leukaemic target CD44v6. fcCAR. CIK were successfully ex-vivo expanded from leukaemic patients in complete remission after HCT confirming their intense preclinical anti-leukaemic activity without enhancing the alloreactivity across human leukocyte antigen (HLA) barriers.

Our study provides translational bases to support clinical studies with fcCAR. CIK, a sort of biological bridge between the autologous and allogeneic sources, as alternative DLI following HCT.